Lv4
738 积分 2023-08-08 加入
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
3个月前
已完结
Finerenone in CKD from Estimands to Clinical Interpretability under Competing Risk
4个月前
已关闭
Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists
4个月前
已完结
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both
4个月前
已关闭
The nonsteroidal MR antagonist finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation
4个月前
已关闭
Effectiveness and safety of finerenone in IgA nephropathy patients
4个月前
已完结
Effect of Finerenone on Morbidity and Mortality in CKD
4个月前
已关闭
Finerenone ameliorates high-fat-induced myocardial lipotoxicity by suppressing ferroptosis through augmenting the system Xc-/GSH synthesis pathway
4个月前
已关闭
Innovative therapeutics for renoprotection: Where we are
4个月前
已完结
Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells
7个月前
已完结
皖公网安备34019202002308
